Every year over two days in November L'Institut Servier organizes Annual Scientific Sessions in Paris, which cover :

● The Laureate Symposium : researchers, medical doctors and/or pharmacists having benefitted from a mobility research grant present their research in the presence of their department head and of the head of their host laboratory.

● The Scientific Colloquium : organized by two members of the Scientific Committee and dedicated to a subject of current and future interest, notably in the following therapeutic domains: cardiovascular diseases, diabetes, neurodegenerative diseases, immune inflammation and oncology.

November 25TH, 2020
Research presentations by the 2020 Laureates
Bernard Devulder, President of the Scientific Committee
Radiological-pathological correlations in lung adenocarcinoma: qualitative and quantitative approaches
Constance de Margerie-Mellon, Éric de Kerviler (Hôpital Saint-Louis, Paris) / Alexander Banquier (Beth Israel Hospital, Boston)
Preclinical study of the immunogenic potential of DNA repair inhibitors in Non-Small Cell Lung Cancer: towards the development of innovative therapeutic combinations with immunotherapy
Roman Chabanon, Jean-Charles Soria (Institut Gustave Roussy, Villejuif) / Christopher Lord (The Institute of Cancer Research, London)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat, Jean-Yves Delattre (Hôpital Pitié-Salpêtrière, Paris) / Keith L. Ligon (Dana Farber Cancer Institute, Boston)

> Watch the video (coming soon)

Development of new sequences in ultra-high field resolution (7T) MRI, and clinical validation in ophthalmologic oncology
Augustin Lecler, Jean-Claude Sadik (Fondation Rothchild, Paris) / Brian Rutt (Center of Imaging, Stanford)
Burkitt lymphoma: role of EBV, HIV and Plasmodium falciparium culture in vivo, and development of an in vitro model
Fatimata Bintou Sall, Awa Oumar Touré (Hôpital A. Le Dantec, Dakar) / Joëlle Wiels (Institut Gustave Roussy, Villejuif)
Preclinical evaluation of 64Cu-DOTHA2-PSMA-617 for theranosticsin prostate cancer
Ophélie Bélissant Benesty, Jean-Noël Talbot (Hôpital Tenon, Paris) / Éric Turcotte (Centre hospitalier universitaire de Sherbrooke, Québec)
Premature coronary artery disease: natural history, prognosis, primary and secondary risk factors
Michel Zeitouni, Gilles Montalescot (Hôpital Pitié-Salpêtrière, Paris) / Matthew T. Roe (Duke Institute, Durham)
Prediction of long-term coronary risk after TIA and cerebral infarction
Marion Boulanger, Emmanuel Touzé (Université de Caen) / Peter Rothwell (John Radcliff Hospital, Oxford)
Study of functional decline in an older population from the MAPT trial (Multidomain Alzheimer Preventive Trial)
Jagadish Kumar Chhetri, Bill Piu Chan (Xuan Wu Hospital, Beijing) / Bruno Vellas (Gérontopole, Toulouse)
Identification and functional analysis of disease causing gene mutations that control macrophage functions in families with severe Systemic Lupus Erythematosus
Stéphanie Guillet, Bertrand Godeau (Hôpital Henri Mondor, Créteil) / Frédéric Geissmann (Mémorial Sloan Kettering Cancer Center, New-York)
Value of allogenic grafts of hematopoietic stem cells in primary immunodeficiency in adults with severe complications
Morgane Cheminant, Olivier Hermine (Hôpital Necker, Paris) / Siobhan Burns (UCL, London)
Thrombocytopinea at hospital admission and mortality risk. A population-based study in Denmark
Guillaume Moulis, Laurent Sailler (CHU Purpan, Toulouse) / Henrik Toft Sorensen (Aarhus University Hospital, Danemark)
Moderate hyperuricemia improves prognosis in acute ischemic renal failure via antioxidant action and metabolic reprogramming of macrophages
Viviane Gnemmi, Isabelle Van Seuningen (CHU Lille) / Hans-Joachim Anders (Klinikum der Universität München)
Alternative macrophages in vascular calcification: what is their role in type 2 diabetic subjects?
Cong Duy Le, Thanh Vy Tran (CHU d’Hô Chi Minh-City) / Giulia Chinetti (CHU de Nice)
Concluding remarks
Christophe Charpentier, General Manager of L’Institut Servier